Prevalence of Non-Alcoholic Fatty Pancreas Disease (NAFPD) and its risk factors among adult medical check-up patients in a private hospital: a large cross sectional study

Cosmas Rinaldi A. Lesmana1,2*, Levina S. Pakasi1, Sri Inggriani3, Maria L. Aidawati3 and Laurentius A. Lesmana1

Abstract

Background: The clinical significance of non-alcoholic fatty pancreatic disease (NAFPD) or fatty pancreas is largely unknown. It is often an incidental finding on abdominal ultrasound, which is not explored further, especially its association with metabolic condition and the risk of pancreatic malignancy. The aim of this study is to evaluate the presence of NAFPD and its associated risk factors among adult medical check-up patients.

Method: A large cross-sectional study was done among adult medical check-up patients underwent abdominal ultrasound between January and December 2013 in Medistra Hospital, Jakarta. Data was obtained from the patients’ medical record and include demographic data, blood pressures, fasting blood glucose level, and lipid profile. The presence of fatty pancreas was diagnosed by ultrasound. Bivariate and multivariate analyses were done to find associated risk factors for NAFPD. Statistical analysis was done using SPSS version 17.

Results: A total of 1054 cases were included in this study; pancreas cannot be visualized in 153 cases and were excluded from the analysis. Fatty pancreas was present in 315 (35.0 %) patients. Bivariate analyses found associations among fatty pancreas and several risk factors such as gender, age, systolic and diastolic blood pressures, body mass index (BMI), fasting plasma glucose (FPG), triglycerides (TG) and cholesterol levels.

Conclusion: Fatty pancreas is a common finding during medical check-up with a prevalence of 35%. Fatty pancreas has significant association with metabolic factors and it might have an important role in risk of malignancy.

Keywords: Fatty pancreas, Metabolic syndrome, Non-alcoholic fatty pancreas disease, Risk factors

Background

High energy intake in human may lead to excessive fat which could be accumulated in visceral organs that are unusual for adipose tissue storage, the so-called ectopic fat [1]. Fatty pancreas or nonalcoholic fatty pancreatic disease (NAFPD) is an excessive fat infiltration of the pancreas due to obesity in the absence of significant alcohol intake [2]. Fatty pancreas is a common ultrasound finding which has increased echogenicity when compared to the normal pancreas [3].

On the contrary to the nonalcoholic fatty liver disease (NAFLD), the potential systemic and local consequences of excessive fat accumulation in the pancreas have not been well established. Fatty infiltration in the pancreas has been showed to correlate with the metabolic risk factors and may represent a meaningful manifestation of metabolic syndrome., [4, 5] Epidemiology study also suggests that obesity is a risk factor for pancreatic cancer [6]. Based on a recent study, fatty infiltration in the pancreas may increase the risk of pancreatic ductal adenocarcinoma beyond the effect of obesity alone [7]. The problem with
the organ location needs the more accurate imaging diagnostic procedures, such as abdominal MRI or even Endoscopic Ultrasound (EUS). The fat content of the pancreas also can be estimated by 3D two point Dixon techniques. However, in population or medical checkup settings, it would be unpractical and also costly to examine the pancreas [8–10].

Since the clinical implication of fatty pancreas is still a matter of debate, especially in countries where alcohol consumption is not an issue, therefore, this study was aimed to evaluate the presence of fatty pancreas and established its associated risk factors.

**Method**

**Study design and subject**

The study design was an analytical cross-sectional study among medical check-up patients in Medistra Hospital which has been approved from the Medistra hospital's local ethics committee between January and December 2013. Inclusion criteria was adult patients aged more than 18 years, no serious illness at the time of examination, having routine laboratory check-up for liver function test, fasting plasma glucose (FPG) levels, and lipid profile, and underwent abdominal ultrasound assessment. None of the patients had a history of significant alcohol drinking (<20 g/day). Patients were excluded from analyses if the pancreas was not visualized on ultrasound or laboratory data was incomplete. Risk factors of NAFPD tested were gender, age group, history of diabetes, body mass index (BMI), systolic and diastolic blood pressures (BP), FPG, triglycerides, total cholesterol, low-density lipoprotein (LDL)-cholesterol, and high-density lipoprotein (HDL)-cholesterol levels. Diabetes mellitus (DM) is diagnosed based on clear history from patient’s interview and the blood glucose database. The metabolic data parameters were collected as the parameters which become our hospital medical check-up standard examination. The minimum sample size for estimating one population proportion at an anticipated proportion of 50 %, 99 % level of confidence and 5 % margin of error was 664 patients.

**Diagnosis of fatty pancreas**

Fatty pancreas or pancreas lipomatosis was diagnosed using abdominal ultrasound technique performed by one experienced radiologist in the hospital using a high-resolution ultrasound machine equipped with a 3.5 MHz convex-array probe (LOGIC S7, GE System, US). The radiologist who performed the ultrasound examinations was blinded to the laboratory data; the results were evaluated by another experienced radiologist to ensure unbiased evaluation. Pancreatic echogenicity was compared to the liver echogenicity at the same depth on a longitudinal scan taken near the abdominal midline [11]. If the liver also showed increased echogenicity, comparison was also made with the renal cortex. Diagnosis of pancreas lipomatosis was established if there is increased echogenicity of the pancreas over the liver or renal cortex.

**Laboratory tests**

All subjects underwent laboratory tests for standard medical check-up consisting of complete peripheral blood test, liver function test, fasting plasma glucose and lipid profiling. These tests were performed after an overnight fast for a minimum of 10 h.

**Statistical analyses**

Characteristics of the study subjects were presented descriptively. Bivariate analyses between the presence of NAFPD and risk factors were performed using the Chi-square test. A p value of less than 0.05 was considered significant. Multivariate logistic regression was used to find independent risk factors for NAFPD. Statistical analysis was done using SPSS version 17.0.

**Results**

**Characteristics of the study subjects**

There were 1054 cases enrolled in the analysis; 720 (68.3 %) of them were men. The mean age was 43.1 ± 12.19 years old. Other characteristics were summarized in Table 1. Pancreas was non-visualized in 153 (14.5 %) cases. In the remaining 901 cases, fatty pancreas was found in 315 (35 %) patients.

**Associations among metabolic risk factors and fatty liver**

The presence of fatty pancreas were significantly associated with male gender, age >35 years, higher systolic and diastolic blood pressures, fasting blood glucose >100 mg/

| Characteristic                      | Mean (SD) | N  | %  |
|------------------------------------|-----------|----|----|
| Male gender                        |           | 720| 68.3|
| Age (years)                        | 43.1 ± 12.19 |    |    |
| Age >35 years old                  |           | 723| 68.6|
| Body mass index (kg/m²)            | 24.9 ± 3.96 |    |    |
| Systolic blood pressure (mmHg)     | 120 ± 37.2 |    |    |
| Diastolic blood pressure (mmHg)    | 75 ± 9.9   |    |    |
| Fasting plasma glucose (mg/dL)     | 96.7 ± 24.69 |   |    |
| Triglyceride levels (mg/dL)        | 127.1 ± 80.15 |  |  |
| Total cholesterol levels (mg/dL)   | 205.4 ± 59.0 |   |    |
| LDL-cholesterol                    | 133.2 ± 35.29 |  |    |
| HDL-cholesterol                    | 51.1 ± 12.87 |    |    |
| NAFPD                               |           |    |    |
| No                                 | 516       |    | 49.0|
| Yes                                | 538       |    | 51.0|
dL, triglycerides, total and LDL-cholesterol, and lower HDL cholesterol levels (Table 2).

**Association between fatty pancreas and fatty liver**

Fatty liver was present in 538 (51.0 %) of the total study subjects. Among 901 patients with visualized pancreas, fatty pancreas coexisted with fatty liver in 232 (25.7 %) patients; both were absent in 381 (42.3 %) patients. In addition, fatty pancreas with normal liver was found in 83 patients (16.0 %) and fatty liver with normal pancreas was seen in 205 (39.4 %) patients. There was a significant association between fatty pancreas and fatty liver (OR: 5.195; 95 %CI: 3.838-7.032; p < 0.001).

When the 381 patients with neither fatty liver nor fatty pancreas were excluded, fatty pancreas coexisted with fatty liver in 232 patients (44.6 %). This number can be broken down further, revealing that fatty pancreas was found in 53.1 % of patients with fatty liver whereas fatty liver can be found in 73.7 % of patients with fatty pancreas (Fig. 1).

**Association between fatty pancreas and diabetes mellitus**

Type 2 diabetes mellitus was present in 62 (6.9 %) of the study subjects and fatty pancreas was detected in 31 (50 %) of them. Statistically, diabetes has significant associated with fatty pancreas (OR 1.953; 95 % CI: 1.164–3.280; p < 0.001). However, when entered into the multivariate analyses; diabetes failed to show a significant association, suggesting that it was a confounding factor rather than an independent risk factor.

**Discussion**

**Characteristics of the study subjects**

With a detection rate of 35 %, our study showed that the prevalence of nonalcoholic fatty pancreas is high among adult patients underwent routine medical check-up. A recent study involving 8097 subjects underwent health check-up in Taiwan found only 16 % prevalence of fatty pancreas detected by abdominal ultrasound [12]. On the contrary, a Korean study found that 67.9 % of 293 subjects visiting an obesity clinic had fatty pancreas detected by abdominal ultrasound. Larger sample size allows more valid generalization into the general population; therefore, the estimated prevalence of fatty pancreas in the real community may be best represented by the Taiwanese study. The subjects of our study might give an over-estimate result because most of our hospital’s medical check-up subjects came from high social economic groups. Our study may also not represent the true Indonesian population since the patients were recruited from a referral private hospital. However, the high prevalence of NAFPD has given a new insight in patient’s follow up and screening as the risk of malignancy might also be increasing. A more accurate estimation might be shown by a recent study among 685 Hong Kong Chinese healthy volunteers; the prevalence of fatty pancreas detected by fat-water magnetic resonance imaging was 16.1 % [13].

**Association between fatty pancreas and metabolic risk factors**

Our results showed significant association between fatty pancreas and metabolic risk factors (Table 2). Table 3 showed independent risk factors to predict fatty pancreas. These results were consistent with previous epidemiological report in Hong Kong Chinese population [10]. The OR of DM and other variables mostly around the value of 2.0; therefore although systolic BP have higher OR, the difference with DM or triglycerides can be considered not too wide. However, the number of subjects with DM is relatively small compared to other variables. It could affect the statistical calculation of OR and may explain the slight difference with systolic BP.

**Table 2** Associations among risk factors and the presence of fatty pancreas (n = 901)

| Risk factor | Fatty pancreas | Odds ratio (95 % CI) | p value |
|-------------|----------------|----------------------|---------|
| Male sex (n = 574) | Yes (n = 315) | 228 (72.4 %) | 346 (59.0 %) | 1.818 (1.351–2.446) | <0.001 |
| Age ≥ 35 years (n = 612) | 268 (85.1 %) | 344 (58.7 %) | 4.011 (2.824–5.697) | <0.001 |
| Systolic BP ≥ 130 mmHg (n = 201) | 99 (31.4 %) | 102 (17.4 %) | 2.175 (1.580–2.994) | <0.001 |
| Diastolic BP ≥ 85 mmHg (n = 111) | 54 (17.1 %) | 57 (9.7 %) | 1.920 (1.286–2.866) | 0.001 |
| Body mass index ≥ 25 kg/m² (n = 390) | 206 (65.4 %) | 184 (31.4 %) | 4.129 (3.088–5.520) | <0.001 |
| Type 2 diabetes mellitus (n = 62) | 31 (9.8 %) | 31 (5.3 %) | 1.954 (1.164–3.280) | 0.010 |
| FPG ≥ 100 mg/dL (n = 187) | 99 (31.4 %) | 88 (15.0 %) | 2.594 (1.867–3.603) | <0.001 |
| Triglycerides ≥ 150 mg/dL (n = 226) | 105 (33.3 %) | 121 (20.6 %) | 1.921 (1.412–2.615) | <0.001 |
| Total cholesterol ≥ 200 mg/dL (n = 491) | 203 (64.4 %) | 288 (49.1 %) | 1.875 (1.415–2.486) | <0.001 |
| LDL-C ≥ 100 mg/dL (n = 742) | 275 (87.3 %) | 467 (79.7 %) | 1.752 (1.189–2.582) | 0.004 |
| HDL-C < 40 mg/dL (n = 194) | 86 (27.3 %) | 108 (18.4 %) | 1.662 (1.202–2.298) | 0.002 |

BMI body mass index, FPG fasting plasma glucose, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol
From the statistical point of view, clinical value of an OR occurs when it is more than 1.5. Compared to age or BMI (which have OR >4.0), the ORs of DM and systolic BP are much weaker, it’s also the same with other variables with OR value less than 2.0. From the metabolic point of view, DM is considered as part of metabolic syndrome with could confound other variables within the metabolic markers group (such as cholesterol or TG). On the other hand, blood pressure is a hemodynamic marker. High blood pressure in metabolic syndrome is a consequence of insulin resistance with various underlying mechanisms [14]. Therefore, higher OR of systolic BP might reflect that is more important as risk factor than DM or other lipid parameters.

**Association between fatty pancreas and fatty liver**

Fatty liver was reported as a predictor of “hyperechogenic pancreas” seen during endoscopic ultrasound [15]. A post-mortem study collected from 80 cadavers found that total pancreatic fat was a significant predictor of NAFLD, but no correlation was found between pancreatic fat and NAFLD activity score after corrected for body mass index [16]. Our study showed significant correlation between fatty pancreas and fatty liver, however whether with these two entities might doubling the risk of malignancy is still unknown.

Despite the presence of statistical association, the pathophysiology underlying both conditions might be coincidence rather than causative. Both fatty pancreas and fatty liver are significantly associated with metabolic risk factors due to excessive energy intake.

**Association between fatty pancreas and diabetes mellitus**

Based on our study, even though there is a significant association between the presence of fatty pancreas and diabetes mellitus, however the association was not observed in the multivariate analysis. Different result was reported among 7464 subjects underwent physical check-up in Taiwan. This might be due to the smaller size effect in the subgroup analysis. The investigators did found an independent association between fatty pancreas and diabetes (OR: 1.379; 95 %CI: 1-047-1.816) [17]. However, this study

| Risk factor                | β    | SE (β) | β/SE | ORadj | 95 % CI       | p value |
|----------------------------|------|--------|------|-------|--------------|---------|
| Age > 35 years             | 1.077| 0.191  | 5.639| 2.936 | 2.020–4.267  | <0.001  |
| BMI ≥ 25 kg/m²              | 1.261| 0.154  | 8.188| 3.529 | 2.607–4.775  | <0.001  |
| FPG ≥ 100 mg/dL            | 0.531| 0.183  | 2.902| 1.701 | 1.189–2.434  | 0.004   |
| Total cholesterol ≥ 200 mg/dL | 0.491| 0.157  | 3.127| 1.634 | 1.201–2.223  | <0.001  |

BMI: body mass index, FPG: fasting plasma glucose

**Table 3** Independent risk factors to predict fatty pancreas (N = 901)
was not designed to establish a direct causal relationship between diabetes mellitus and fatty pancreas or vice versa and should be interpreted as such. The complex factor in insulin resistance pathway might play an important factor. High free fatty acid (FFA) will induce the accumulation of pancreatic fat and the fat deposition will disrupt the beta cell function. The beta cell dysfunction results in unmet relative insulin need to maintain optimal glycemic control and in combination with insulin resistance at the pathway synergistically contributes to the long-term hyperglycemia. This is an important pathway for the development of diabetes mellitus. In return, the insulin resistance condition where induced by FFA source in the pancreas might induce the chronic inflammation stage where this can become a malignancy risk [18]. With these findings, we might also need to screen our diabetes patients for pancreatic malignancy risk.

This study has several limitations. First, the study was designed as a cross-sectional study which cannot prove causal link between fatty pancreas and the associated factors. However, the large sample size in this study could provide generalization to the larger population of interest. Body mass index (BMI) as a risk for pancreatic lipomatosis might be a confounding factor to detect the presence of fatty pancreas. Second, the data about diabetes medication not being reported based on our MCU standard examination record. But this study has given the importance of metabolic factors associated with the presence of NAFPD. Third, the need to differentiate between simple steatosis and steatosis with inflammation in the pancreas has not been elucidated. The transabdominal ultrasound study might not be the best of choice, but ultrasound is still a qualified technique in an experienced hand, and also cheaper when compared to MRI in the community setting. Further study with ethical consideration will be needed to perform pancreas biopsy using EUS study.

Conclusion
The prevalence of NAFPD in Indonesia is high and it is strongly correlated with other metabolic conditions. The clinical significance of routine fatty pancreas screening needs to be included in our clinical practice. However, it would need further investigation about the long standing condition of fatty pancreas and the usefulness of pancreatic biopsy to see the possibility of disease progression.

Abbreviations
NAFPD: Non-alcoholic Fatty Pancreas Disease; NAFLD: Non-alcoholic Fatty Liver Disease; EUS: Endoscopic Ultrasound; BMI: Body Mass Index; FPG: Fasting Plasma Glucose; TG: Triglyceride; LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein; BP: Blood Pressure.

Competing interests
The authors declare that they have no competing interests.

Author contribution
CRAL and LSP designed and conducted the study; LSP performed statistical analysis and drafted the manuscript. SR, MLA performed abdominal ultrasound, interpreted the data and contributed to the discussion. LAL supervised the study and contributed to the discussion, edited and approved the manuscript. All authors read and approved the manuscript.

Author details
1Digestive Disease & GI Oncology Center, Medistra Hospital, Jakarta, Indonesia. 2Department of Internal Medicine, Hepatobiliary Division, Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia. 3Department of Radiology, Medistra Hospital, Jakarta, Indonesia.

Received: 23 February 2015 Accepted: 1 December 2015
Published online: 12 December 2015

References
1. Britton KA, Fox CS. Ectopic fat depots and cardiovascular disease. Circulation. 2011;124:e837–41.
2. Mathur A, Marine M, Lu D, Swartz-Basile DA, Saxena R, Zyromski NJ, et al. Nonalcoholic fatty pancreas disease. HPB (Oxford). 2007;9:312–8.
3. Marks WM, Filly RA, Callen PW. Ultrasonic evaluation of normal pancreatic echogenicity and its relationship to fat deposition. Radiology. 1980;137:475–9.
4. Lee JS, Kim SH, Jun DW, Han JH, Jang EC, Park JY, et al. Clinical implications of fatty pancreas: correlations between fatty pancreas and metabolic syndrome. World J Gastroenterol. 2009;15:1869–75.
5. Wu WC, Wang CY. Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: case–control retrospective study. Cardiovasc Diabetol. 2013;12:77 (6 pages).
6. Patel AV, Rodriguez C, Bernstein L, Chao A, Thun MJ, Calle EE. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. Cancer Epidemiol Biomarkers Prev. 2005;14:459–66.
7. Hori M, Takahashi M, Hiraoka N, Yamaji T, Mutoh M, Ishigamori R, et al. Association of pancreatic fatty infiltration with pancreatic ductal adenocarcinoma. Clin Translat Gastroenterol. 2014;5:e53. doi:10.1038/ctg.2014.5.
8. Sandrasegaran K, Lin C, Ahiskik FM, Tann M. State of the art pancreatic MRI. Am J Radiol. 2010;195:42–53.
9. Sijens PE, Edens MA, Bakker SJ, Stolk RP. MRI determined fat content of human liver, pancreas and kidney. World J Gastroenterol. 2010;16(19):1993–8.
10. Powis ME, Chang KJ. Endoscopic ultrasound in the clinical staging and management of pancreatic cancer: its impact on cost of treatment. Cancer Control. 2000;7(3):1413–20.
11. Worthen NJ, Beabeu D. Normal pancreatic echogenicity: relatin to age and body fat. AJR. 1982;139:1095–8.
12. Wang C-Y, Ou H-Y, Chen M-F, Chang T-C, Chang C-J. Enigmatic ectopic fat: mechanisms for development of hypertension in the metabolic syndrome. J Am Heart Assoc. 2014;3:e000297.
13. Wong VW, Wong GL, Yeung DK, Abrigo JM, Kong AP, Chan RS, et al. Fatty pancreas insulin resistance, and β-cell function: a population study using fat-water resonance imaging. Am J Gastroenterol. 2014;109:589–97.
14. Yanai H, Tomono Y, Ito K, Furutani N, Yoshida H, Tada N. The underlying mechanisms for development of hypertension in the metabolic syndrome. Nutr J. 2009;8:10.
15. AHaddad M, Khashab M, Zyromski N, Pungpapong S, Wallace MB, Scalapino J, et al. Risk factors for hypercholesteric pancreas on endoscopic ultrasound: a case–control study. Pancreas. 2009;38:672–5.
16. van Geenen EJ, Smits MM, Schreuder TC, van der Peet DL, Bloemenda E, Mulder CJ. Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. Pancreas. 2010;39:1185–90.
17. Ou H-Y, Wang C-Y, Yang Y-C, Chen M-F, Chang C-J. The association between nonalcoholic fatty pancreas disease and diabetes. PLoS ONE. 2013;8:e62561.
18. Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol. 2013;4(37):1–7.